Pharmaceutical giant Regeneron Pharmaceuticals Inc has announced its drug-development ally Sanofi SA plans to increase its stock in the pharma company through a 5.3 percent purchase. In a statement, Sanofi said it is allowed to build its stock in Regeneron to up to 30 percent; Sanofi controls 16.7 percent currently, according to reports. Sanofi also denied speculation that the company is going after a controlling stake in the pharmaceutical company. The two have a longstanding partnership in drug development.
Featured News
The Hidden Security Risk Inside Your Company’s AI Tools
Mar 13, 2026 by
CPI
EU’s Largest Economies Push to Reduce Reliance on Foreign Payment Systems
Mar 12, 2026 by
CPI
Warren Presses Amazon for Answers on Pricing Practices for Government Buyers
Mar 12, 2026 by
CPI
EU Antitrust Chief Raises Concerns Over Big Tech Control of AI
Mar 12, 2026 by
CPI
Burson Adds Senior Advisor to Strengthen Competition Team
Mar 12, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece